Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow ARQT
Arcutis Biotherapeutics, Inc. (ARQT) EV/Sales
As of 16 October 2026, Arcutis Biotherapeutics, Inc. (ARQT) trades at a EV/Sales of 7.8×. Over the past ten years it has ranged from 0.0× (June 2023) to 51.9× (July 2023); the current reading is higher than 75% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 9.5× | 12.58% |
| FY2024 | 8.5× | 201.21% |
| FY2023 | 2.8× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.1× | 0.55% |
| Mar 2026 | 7.1× | (25.92%) |
| Dec 2025 | 9.5× | 30.39% |
| Sep 2025 | 7.3× | 13.40% |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| VKTX Viking Therapeutics, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 2.0× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 2.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.3× |
| ARQT Arcutis Biotherapeutics, Inc. | 7.8× |
| TNGX Tango Therapeutics, Inc. compare | 36.7× |
| XENE Xenon Pharmaceuticals Inc. compare | 144× |
| RLAY Relay Therapeutics, Inc. compare | 217× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)